EVALUATING THE EFFECT OF PIRFENIDONE COMPARED WITH PLACEBO IN PULMONARY FIBROSIS POST-COVID 19 : A RANDOMIZED PHASE-II CLINICAL TRIAL TO EVALUATE THE EFFECT OF PIRFENIDONE COMPARED WITH PLACEBO IN PULMONARY FIBROSIS POST-COVID 19:

Medienart:

Klinische Studie

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

WHO International Clinical Trials Registry Platform - (2020) vom: 07. Dez. Zur Gesamtaufnahme - year:2020

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: Pulmonary fibrosis induced by SARS-COV2 virus (post-COVID19 pulmonary sequelae) MedDRA version: 21.0Level: PTClassification code 10037383Term: Pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 23.0Level: HLTClassification code 10084510Term: Coronavirus infectionsSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Phase: Phase 2
Recruitment Status: Authorised-recruitment may be ongoing or finished
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 28-10-2020, Last updated: 2022-11-24

ICTRP ID:

EUCTR2020-002518-42-ES
FIBRO-COVID

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG004385012